louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06191770: Comparison of Morphine With Nalbuphine in a Multimodal Approach for Pain Relief in Patients Undergoing Gynecological Procedures: Randomized Controlled Double Blind Clinical Trial
Official title: Comparison of Morphine With Nalbuphine in a Multimodal Approach for Pain Relief in Patients Undergoing Gynecological Procedures: Randomized Controlled Double Blinded Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Acute
Lead sponsor: Aga Khan University Hospital, Pakistan
Sponsor class: OTHER
First posted: 2024-01-05
Enrollment: 66
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two groups
Primary purpose: TREATMENT

Brief summary: This study was conducted in the Aga Khan University Hospital, Karachi. Pakistan is developing country and overall shortage of Morphine in developing country.

Rationalizing, in multimodal analgesia, Nalbuphine is equivalent to morphine in open Abdominal hysterectomy

Detailed description: A large number of patients undergoing major surgical procedures need gold standard analgesic like morphine for adequate pain control. Shortage of Morphine results in inadequate pain relief leading to delayed recovery, prolonged hospitalization and persistent post-surgical pain syndrome.

For better surgical outcome, there is a strong need to find an alternative to morphine in a multi modal analgesia that help optimize pain relief with less opioids in patients undergoing gynecological procedures

Eligibility criteria: Inclusion Criteria:

* All ASA I and ASA II women, age b/w 18-59 scheduled for Elective open moderate to major gynecological procedures at Aga Khan University Hospital

Exclusion Criteria:

* Patient is unwilling to participate or provide informed consent History of chronic pain or pain syndrome with concurrent opioid medication use Fibromyalgia Patient has received opioids and/or tramadol in the past 4 hours History of adverse reaction to morphine, ketamine and nalbuphine Presence of oxygen dependent pulmonary disease, liver cirrhosis or renal disease requiring dialysis.

Presence of Ischemic heart disease Presence of intracranial mass or vascular lesion. Presence of psychosis or hallucinations Weight greater than 115kg or less than 45 kg

Primary outcomes:
measure: Morphine Versus Nalbuphine in a multimodal Analgesia for Patients undergoing Gynecological Procedures: A double blind randomized controlled trial
timeFrame: 1 year
Secondary outcomes:
measure: Morphine Versus Nalbuphine in a multimodal Analgesia for Patients undergoing Gynecological Procedures: A double blind randomized controlled trial
timeFrame: 1 year
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Gauhar Afshan
state: Sindh
Study officials:
References:
Clinical trial NCT02771470: Intestinal Microflora in Lung Cancer After Chemotherapy
Official title: Intestinal Microflora in Lung Cancer After Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Lung Cancer
Effects of Chemotherapy
Tumor Immunity
Malnutrition
Keywords: Gut microflora
Lung cancer
Chemotherapy
Immunity
Nutrition
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2016-05-13
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Probiotics modulate the gut microflora and immune status in lung cancer who need chemotherapy.

Detailed description: Chemotherapy destroys the intestinal mucosal barrier, affects intestinal flora, causing bacterial translocation, infection and other complications. Probiotics may restore the intestinal immunity, mucosal barrier and nutrient absorption.

Eligibility criteria: Inclusion Criteria:

* Patients scheduled for chemotherapy of lung cancer

Exclusion Criteria:

* Antibiotic, probiotic or prebiotic usage within 1month
* Other malignancy
* History of abdominal surgery
* Pregnant or breast-feeding (for females)
* Impaired liver or renal function
* Diabetes, thyroid disorder, coagulopathy or bleeding disorders, mental disorder

Primary outcomes:
measure: Composition of Microorganisms in stool after probiotic intervention
timeFrame: 2 months
Secondary outcomes:
measure: Frequency and severity of Adverse effects during Chemotherapy
timeFrame: 2 months
measure: The change of immunity and nutrition index
timeFrame: 2 months
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of Gastroenterology,Qilu Hospital,Shandong University
state: Shandong
Study officials:
affiliation: Qilu Hospital, Shandong University
name: Yanqing Li, MD.PhD.
role: STUDY_CHAIR
References:
Clinical trial NCT00387270: Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
Official title: A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Huntington's Disease
Keywords: Huntington's disease
Dimebon
dose-escalation
Phase 1-2a
randomized
controlled
double-blind
Unified Huntington's Disease Rating Scale
Lead sponsor: Medivation, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Huntington Study Group
First posted: 2006-10-12
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.


Eligibility criteria: Inclusion Criteria:

* Clinical features of Huntington's disease and a confirmatory family history of HD, or a CAG repeat expansion greater than or equal to 36
* Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the Unified Huntington's Disease Rating Scale

Exclusion Criteria:

* Clinical evidence of unstable medical illness

Primary outcomes:
measure: Dose-limiting toxicities
timeFrame: 7 days
Secondary outcomes:
measure: Unified Huntington's Disease Rating Scale
timeFrame: 7 days
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Huntington Study Group
state: New York
Study officials:
affiliation: University of Rochester Medical School, Huntington Study Group
name: Karl D Kieburtz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06427070: Effectiveness of Two Intracanal Irrigation Solutions
Official title: Effectiveness of Two Intracanal Irrigation Solutions Delivered Through Cryotherapy on Post-Endodontic Pain Relieve. A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Irreversible Pulpitis
Keywords: Pulpitis
CHX
Saline
Lead sponsor: Misr University for Science and Technology
Sponsor class: OTHER
First posted: 2024-05-23
Enrollment: 1
Sex: MALE
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the present clinical trial is to investigate and compare the effect of crayotherapy utilizing two intra-canal final irrigating solutions on postoperative pain.

Detailed description: 1. st: Comparison of pain reduction algorism after cryotherapy using the two tested irrigating materials
2. nd. Number and frequency of analgesics taken for pain relief during one week postoperative

Eligibility criteria: Inclusion Criteria:

* Case diagnosed as having symptomatic irreversible pulpitis with symptomatic apical periodontitis
* Patients requiring emergency RCT
* Pre-operative pain score 7 on Numerical Rating (NRS) scale
* Middle aged males (25-50)
* Medical profile ASA1
* Willing to sign the consent form
* Willing to answer our call for one week period

Exclusion Criteria:

* Females
* Medical conditions above ASA1
* Multi-rooted teeth
* Patients younger or older than (25-50)

Primary outcomes:
measure: pain scale
timeFrame: 1 week
measure: Analgesics Frequency
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06845670: Effects of Wurn Technique on Dyspareunia, Menstrual Cramps & QoL in Infertile Women
Official title: Effects of Wurn Technique on Symptoms of Dyspareunia, Menstrual Cramps and Quality of Life in Women With Infertility
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility, Female
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2025-02-25
Enrollment: 54
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Wurn technique is a PT technique. It is site specific massage therapy in the form of relaxing technique, helps to promote the function of abdominopelvic and reproductive organs.

Detailed description: This study will be randomized controlled trial, will be completed in 10 months duration. Non probability Conveninence sampling technique will be used with 54 participants after randomization. Effect will be obseved in 2 groups.

Eligibility criteria: Inclusion Criteria:

* Women with infertility between age 25 to 45
* women who were unable to conceive for 12months with regular unprotected intercourse
* women with infertility indicating sexual pain, irregular periods with menstrual cramps.
* women with secondary infertility

Exclusion Criteria:

* Women with active infections and abnormal ovarian cysts.
* Any abdominopelvic surgery within last 90days.
* Any medical history of active abdominopelvic cancer or malignancy.

Primary outcomes:
measure: Female Sexual Function Index Scoring
timeFrame: 2weeks duration
measure: Mankoski Pain Scale
timeFrame: 2weeks duration
measure: FertiQoL
timeFrame: 2weeks duration
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Riphah International University
Study officials:
affiliation: Riphah International University
name: Adeela Arif, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04426370: The Effects of Social Role Participation on Life Quality
Official title: The Effects of Social Role Participation on Life Quality in Rheumatoid Arthritis Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Social Interaction
Lead sponsor: Recep Tayyip Erdogan University Training and Research Hospital
Sponsor class: OTHER
First posted: 2020-06-11
Enrollment: 195
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 100 RA patients and 95 healthy volunteer control

Brief summary: The study was carried out among 100 RA patients (age from 20 to 70 years) by fulfilling the American College of Rheumatology 1987 revised criteria admitted to our outpatient clinic. RA patients were compared with 95 healthy volunteer control group. Participants were asked to complete interview based questionnaires regarding pain, life quality, and social role participation to obtain additional information during the interview to participate in the study in 20 min.

Detailed description: The study was carried out among 100 RA patients (age from 20 to 70 years) by fulfilling the American College of Rheumatology 1987 revised criteria admitted to our outpatient clinic. RA patients were compared with 95 healthy volunteer control group. Healthy volunteers were recruited from the partners next to the patients who came to our outpatient clinic for examination. The same physician carried out the physical examinations on all participations and conducted a interview, acquiring information on age, gender, body mass index (BMI), marriage status, living alone, working, and education. Participants were asked to complete interview based questionnaires regarding pain, life quality, and social role participation to obtain additional information during the interview to participate in the study in 20 min. Examinations took place at the our outpatient clinic. This study did not include all participants who had accompanying of other rheumatic diseases, musculoskeletal diseases, the presence of another chronic disease, cancer.

Eligibility criteria: Inclusion Criteria:The study was carried out among RA patients (age from 20 to 70 years) by fulfilling the American College of Rheumatology 1987 revised criteria admitted to our outpatient clinic -

Exclusion Criteria:This study did not include all participants who had accompanying of other rheumatic diseases, musculoskeletal diseases, the presence of another chronic disease, cancer.

-

Primary outcomes:
measure: Social role participation
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06800170: Treatment of Menstrual Cycle Alterations in Adolescents
Official title: Treatment of Menstrual Cycle Alterations in Adolescents
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Amenorrhea
Oligomenorrhea
PCOS (Polycystic Ovary Syndrome)
Keywords: myo-Inositol
Dioscorea Villosa
adolescents
Lead sponsor: Lo.Li.Pharma s.r.l
Sponsor class: INDUSTRY
First posted: 2025-01-29
Enrollment: 20
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the aim of the present study is intended to evaluate how treatment with Myo-Inositol and Dioscorea Villosa can help improve menstrual cycle irregularities in adolescents, both with and without PCOS.

Detailed description: The present study aims to evaluate the possible beneficial effect of a treatment with Inofolic HP combined with Inofolic phD on the improvement if menstrual cycle alteration in adolescent patients with or without PCOS.

The molecules chosen for the study are the following: myo-Inositol, α-lactalbumin, Dioscorea Villosa, and Vitamin D, are already commercialized as dietary supplements, commonly administered at same dosage provided in the present study, also for prolonged treatments, with no side effects associated.

Eligibility criteria: Inclusion Criteria:

* adolescent women aged 14-19 years old, with at least 3 years passed after menarche, and oligomenorrhea or amenorrhea

Exclusion Criteria:

* Primary amenorrhea.
* Hyperandrogenism due to other factors (i.e. adrenal hyperplasia or Cushing syndrome).
* Hyperprolactinemia or overt hypothyroidism (TSH ≥4).
* Other hormonal alterations.
* Ongoing hormonal therapies, including OCPs, six months before enrollment.
* Ongoing pharmacological therapies.
* Ongoing use of myo-Inositol supplement or other source of myo-Inositol, or Dioscorea villosa, six months before enrollment.

Primary outcomes:
measure: Menstrual cycle regularity
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tbilisi
country: Georgia
facility: Zhordania and Khomasuridze Institute of Reproductology
city: Rome
country: Italy
facility: Agunco
city: Saint Petersburg
country: Russian Federation
facility: Department of Obstetrics and Gynecology with Reproductive Medicine, F.I. Inozemtsev Academy of Medical Education
Study officials:
References:
Clinical trial NCT00595270: Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
Official title: Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Japanese Encephalitis
Lead sponsor: Valneva Austria GmbH
Sponsor class: INDUSTRY
First posted: 2008-01-16
Enrollment: 349
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The study investigates the long term persistence the Japanese encephalitis vaccine IC51 and the need of a booster dose

Detailed description: This is an open label, non-randomized multi-center phase 3 follow-up study. All volunteers having completed trial IC51-304 (NCT00595790) will be enrolled into this trial at 2 sites

Eligibility criteria: Inclusion Criteria:

* At least 18 years of age
* Written informed consent obtained prior to study entry
* Subjects correctly included in and having completed study IC51-304 according to the protocol.

Exclusion Criteria:

* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period
* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy
* Pregnancy, lactation or unreliable contraception in female subjects

Primary outcomes:
measure: Long Term Immunogenicity of IC51 Vaccine 24 Months After the Primary Vaccination
timeFrame: - 24 months
Secondary outcomes:
measure: SPR 24 Months After the Primary Vaccination (Observed)
timeFrame: 24 months
measure: Persistent and Actual SPR 6, 12 and 24 Months After Primary Vaccination
timeFrame: - 24 months
measure: Persistent and Actual GMT 6, 12 and 24 Months After Primary Vaccination
timeFrame: 24 months
measure: SCR 1 Month After the Booster Doses
timeFrame: 1 month
measure: GMT 1month After Booster Doses
timeFrame: 1 month
measure: Safety Profile of IC51
timeFrame: study duration
Other outcomes:
Locations:
Study officials:
affiliation: Valneva Austria GmbH
name: Susanne Eder
role: STUDY_DIRECTOR
References:
Clinical trial NCT03541070: The Effect of Kinesiology Taping on Balance in Duchenne Muscular Dystrophy
Official title: The Effect of Kinesiology Taping on Balance in Duchenne Muscular Dystrophy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Balance
Duchenne Muscular Dystrophy
Keywords: kinesiology taping
balance
Duchenne Muscular Dystrophy
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2018-05-30
Enrollment: 45
Sex: MALE
Minimum age (years): 5
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Investigators investigated that the effects of kinesilogy taping on balance in patients with Duchenne Muscular Dystrophy

Detailed description: Forty-five patients from Level 1 and 2 according to the Brooke Lower Extremity Functional Classification were included in the study. Balance was assessed by Pediatric Berg Balance Test (PBBT), Timed and Go Test (TUGT), and standing on one leg test. Kinesiology taping (KT) with facilitation technique was applied on bilateral quadriceps and tibialis anterior muscles and the assessments were repeated 1 hour after application. The comparison between before and after taping was analyzed.

Eligibility criteria: Inclusion Criteria:

DMD diagnosis being Level I and II according to Brooke Lower Extremity Functional Classification no cooperation problem no injury or orthopedic/neurologic surgery within the past 6 months no severe contracture at ankle

Exclusion Criteria:

children who did not meet the above criteria were not included

Primary outcomes:
measure: Balance Test-Timed up and go test
timeFrame: About 15 seconds
Secondary outcomes:
measure: Pediatric Berg Balance Test
timeFrame: 15 minutes
measure: duration in standing on one leg
timeFrame: about 1 minute
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University
state: Sıhhiye
Study officials:
affiliation: Hacettepe University
name: Güllü Aydın, R.A
role: PRINCIPAL_INVESTIGATOR
affiliation: Hacettepe University
name: İpek Alemdaroğlu Gürbüz, Assoc. Prof.
role: PRINCIPAL_INVESTIGATOR
affiliation: Hacettepe University
name: Öznur Yılmaz, Prof.
role: PRINCIPAL_INVESTIGATOR
affiliation: Hacettepe University
name: Ayşe Karaduman, Prof.
role: PRINCIPAL_INVESTIGATOR
affiliation: Hacettepe University
name: Numan Bulut, R.A
role: PRINCIPAL_INVESTIGATOR
affiliation: Hacettepe University
name: Haluk Topaloğlu, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01249170: Communication Skills Training and Competency Assessment for Pulmonary and Critical Care Medicine Fellows
Official title: Communication Skills Training and Competency Assessment for Pulmonary and Critical Care Medicine Fellows
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Communication
Keywords: Communication skills
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2010-11-29
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: Study to determine if pulmonary/critical care fellows will demonstrate increased competency in the behavioral skills necessary to facilitate family meetings focused on discussions of goals of care in the ICU from pre- to post-communication skills training.

Detailed description: The investigators hypothesize that pulmonary/critical care fellows will demonstrate increased competency in the behavioral skills necessary to facilitate family meetings focused on discussions of goals of care in the ICU from pre- to post-communication skills training.

Eligibility criteria: Inclusion Criteria:

* First- and second-year pulmonary/critical care fellows

Primary outcomes:
measure: Subject self evaluation of training and skill
timeFrame: Measured at basline (Month 0)
Secondary outcomes:
measure: Self versus trainer comparison assessment
timeFrame: Measured at basline (Month 0), during intervention and End of Study (Month 12)
measure: Evaluation of Effectiveness of intervention
timeFrame: Measured at End of Study (Month 12)
measure: Evaluate communication skills curriculum
timeFrame: Measured at End of Study (Month 12)
Other outcomes:
Locations:
city: Columbus
country: United States
facility: The Ohio State University
state: Ohio
Study officials:
affiliation: Ohio State University
name: Jennifer McCallister, M.D.
role: PRINCIPAL_INVESTIGATOR
References: